|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fassina A, Cappellesso R and Fassan M:
Classification of non-small cell lung carcinoma in transthoracic
needle specimens using microRNA expression profiling. Chest.
140:1305–1311. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Garzon R, Calin GA and Croce CM: MicroRNAs
in cancer. Annu Rev Med. 60:167–179. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Oom AL, Humphries BA and Yang C:
MicroRNAs: Novel players in cancer diagnosis and therapies. BioMed
Res Int. 2014:9594612014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li J, Wang Y, Luo J, Fu Z, Ying J, Yu Y
and Yu W: miR-134 inhibits epithelial to mesenchymal transition by
targeting FOXM1 in non-small cell lung cancer cells. FEBS Lett.
586:3761–3765. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang P, Lv HY, Zhou DM and Zhang EN:
miR-204 suppresses non-small-cell lung carcinoma (NSCLC) invasion
and migration by targeting JAK2. Genet Mol Res. 15:gmr64152016.
|
|
9
|
Zhou YL, Xu YJ and Qiao CW: MiR-34c-3p
suppresses the proliferation and invasion of non-small cell lung
cancer (NSCLC) by inhibiting PAC1/MAPK pathway. Int J Clin Exp
Pathol. 8:6312–6322. 2015.PubMed/NCBI
|
|
10
|
Xiao P, Liu W and Zhou H: miR-200b
inhibits migration and invasion in non-small cell lung cancer cells
via targeting FSCN1. Mol Med Rep. 14:1835–1840. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang JG, Wang JJ, Zhao F, Liu Q, Jiang K
and Yang GH: MicroRNA-21 (miR-21) represses tumor suppressor PTEN
and promotes growth and invasion in non-small cell lung cancer
(NSCLC). Clin Chim Acta. 411:846–852. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Duan B, Guo T, Sun H, Cai R, Rui Q and Xi
Z: miR-205 as a biological marker in non-small cell lung cancer.
Biomed Pharmacother. 91:823–830. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ye L, Wang H and Liu B: miR-211 promotes
non-small cell lung cancer proliferation by targeting SRCIN1.
Tumour Biol. 37:1151–1157. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li T, Ding ZL, Zheng YL and Wang W:
MiR-484 promotes non-small-cell lung cancer (NSCLC) progression
through inhibiting Apaf-1 associated with the suppression of
apoptosis. Biomed Pharmacother. 96:153–164. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sun H, Cui C, Xiao F, Wang H, Xu J, Shi X,
Yang Y, Zhang Q, Zheng X, Yang X, et al: miR-486 regulates
metastasis and chemosensitivity in hepatocellular carcinoma by
targeting CLDN10 and CITRON. Hepatol Res. 45:1312–1322. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tan K, Huang G and Fang Q: MiR-486-5p
prevents migration, invasion and EMT by regulating smad2 in breast
cancer. Int J Clin Exp Med. 10:8942–8949. 2017.
|
|
17
|
Alexander MS, Casar JC, Motohashi N,
Vieira NM, Eisenberg I, Marshall JL, Gasperini MJ, Lek A, Myers JA,
Estrella EA, et al: MicroRNA-486-dependent modulation of
DOCK3/PTEN/AKT signaling pathways improves muscular
dystrophy-associated symptoms. J Clin Invest. 124:2651–2667. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu J, Li R, Workeneh B, Dong Y, Wang X and
Hu Z: Transcription factor FoxO1, the dominant mediator of muscle
wasting in chronic kidney disease, is inhibited by microRNA-486.
Kidney Int. 82:401–411. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li Y, Ma C, Qian M, Wen Z, Jing H and Qian
D: Downregulation of NOB1 suppresses the proliferation and tumor
growth of non-small cell lung cancer in vitro and in
vivo. Oncol Rep. 31:1271–1276. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang Y, Li Y, Wu B, Shi C and Li C:
MicroRNA-661 promotes non-small cell lung cancer progression by
directly targeting RUNX3. Mol Med Rep. 16:2113–2120. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ke Y, Zhao W, Xiong J and Cao R: MiR-149
inhibits non-small-cell lung cancer cells emt by targeting FOXM1.
Biochem Res Int. 2013:5067312013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li W, Wang Y, Zhang Q, Tang L, Liu X, Dai
Y, Xiao L, Huang S, Chen L, Guo Z, et al: Correction: MicroRNA-486
as a biomarker for early diagnosis and recurrence of non-small cell
lung cancer. PLoS One. 11:e01485892016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shao Y, Shen YQ, Li YL, Liang C, Zhang BJ,
Lu SD, He YY, Wang P, Sun QL, Jin YX, et al: Direct repression of
the oncogene CDK4 by the tumor suppressor miR-486-5p in non-small
cell lung cancer. Oncotarget. 7:34011–34021. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang X, Zhang T, Yang K, Zhang M and Wang
K: miR-486-5p suppresses prostate cancer metastasis by targeting
Snail and regulating epithelial-mesenchymal transition. OncoTargets
Ther. 9:6909–6914. 2016. View Article : Google Scholar
|
|
26
|
Yi Y, Lu X, Chen J, Jiao C, Zhong J, Song
Z, Yu X and Lin B: Downregulated miR-486-5p acts as a tumor
suppressor in esophageal squamous cell carcinoma. Exp Ther Med.
12:3411–3416. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang J, Tian X, Han R, Zhang X, Wang X,
Shen H, Xue L, Liu Y, Yan X, Shen J, et al: Downregulation of
miR-486-5p contributes to tumor progression and metastasis by
targeting protumorigenic ARHGAP5 in lung cancer. Oncogene.
33:1181–1189. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ding CB, Yu WN, Feng JH and Luo JM:
Structure and function of Gab2 and its role in cancer (Review). Mol
Med Rep. 12:4007–4014. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tian LQ, Liu EQ, Zhu XD, Wang XG, Li J and
Xu GM: MicroRNA-197 inhibits cell proliferation by targeting GAB2
in glioblastoma. Mol Med Rep. 13:4279–4288. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lee SH, Jeong EG, Nam SW, Lee JY, Yoo NJ
and Lee SH: Increased expression of Gab2, a scaffolding adaptor of
the tyrosine kinase signalling, in gastric carcinomas. Pathology.
39:326–329. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gu DH, Mao JH, Pan XD, Zhu H, Chen X,
Zheng B and Shan Y: microRNA-302c-3p inhibits renal cell carcinoma
cell proliferation by targeting Grb2-associated binding 2 (Gab2).
Oncotarget. 8:26334–26343. 2017.PubMed/NCBI
|
|
32
|
Xu XL, Wang X, Chen ZL, Jin M, Yang W,
Zhao GF and Li JW: Overexpression of Grb2-associated binder 2 in
human lung cancer. Int J Biol Sci. 7:496–504. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xu LJ, Wang YC, Lan HW, Li J and Xia T:
Grb2-associated binder-2 gene promotes migration of non-small cell
lung cancer cells via Akt signaling pathway. Am J Transl Res.
8:1208–1217. 2016.PubMed/NCBI
|
